IsoPlexis is empowering the ability to discover sources of inflammatory disease progression and translate those to therapeutic insight
By finding the small groups of highly dysfunctional immune cells that are driving progression, IsoPlexis is working with leaders to address challenges across inflammatory diseases, related to understanding sources of progression with an ability to translate this information to therapeutic insight. These insights are helping evolve the areas of:
Inflammatory & Autoimmune Disease
Join us to learn more about how we are accelerating inflammatory disease programs across the discover-optimize-predict continuum with our unique cellular analysis metrics
IsoPlexis systems are revealing differences in T cell subtypes that correlate with SLE (systemic lupus) progression
Our products uncover the innate cell mechanism driving disease progression, which helps reveal optimal targets
Our systems have stratified patients by CRS (cytokine release syndrome) in cell therapy, pre-infusion
on our datasets >[/ce_button]
Phenotypic and Functional Heterogeneity of cTfh Cells in Systemic Lupus Erythematosus. Kwak M, Choi JY, Craft J, Fan R. Presented at FOCiS Annual Meeting 2016.
JAK-STAT Pathway Activation in Malignant and Non-Malignant Cells Contributes to MPN Pathogenesis and Therapeutic Response. Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, Abdel-Wahab OI, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Murakami M, Radimerski T, Michor F, Fan R, and Levine RL. Cancer Discovery, 5 (3), 316-31 (2015).
Preinfusion Polyfunctional Anti-CD19 Chimeric Antigen Receptor T Cells Associate with Clinical Outcomes in NHL. Rossi J, Paczkowski P, Shen Y, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, Mackay S, Heath JR, Rosenberg SA, Kochenderfer JN, Zhou J, and Bot A. Blood 2018.